Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

9 Months Ended

Sep. 30, 2018

12.

Accrued Expenses and Other Long-Term Liabilities

Accrued expenses and other long-term liabilities, excluding National, consisted of the following:

	September 30, 2018		December 31, 2017
Accrued Expenses:
Professional fees	$	1,471	$	1,625
Salaries, bonuses and related benefits		4,349		5,279
Accrued expenses - related party		50		95
Research and development		3,036		1,873
Milestones related to license agreement		2,500		800
Manufacturing		1,411		1,188
Clinical supplies		2,619		85
License maintenance fees		454		100
Dr. Falk Pharma milestone (See Note 16)		1,300		3,059
Accrued royalties payable		1,045		1,411
Deferred coupon funding		1,490		1,087
Other		644		1,030
Total accrued expenses	$	20,369	$	17,632

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		4,961		4,739
Total other long-term liabilities	$	4,961	$	4,739

National’s accounts payable and other accrued expenses as of June 30, 2018 and September 31, 2017, consisted of the following: